MRX 34

Drug Profile

MRX 34

Alternative Names: miR-34 - Synlogic; miR-34 mimic - Synlogic; MRX-01; MRX34

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asuragen
  • Developer Cancer Prevention & Research Institute of Texas; Mirna Therapeutics
  • Class Antineoplastics; MicroRNAs
  • Mechanism of Action Tumour suppressor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Liver cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Aug 2017 Synlogic has merged with Mirna Therapeutics forming Synlogic
  • 09 May 2017 Mirna Therapeutics withdraws a phase II trial prior to enrolment for Melanoma and Renal cell carcinoma (IV)
  • 09 May 2017 Mirna Therapeutics closes IND application filed with the US FDA for Liver cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top